Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1403380 | Other Identifier | Company Internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 0.01% ointment | Active Comparator | Lowest concentration |
|
| 0.03% ointment | Active Comparator | Middle concentration |
|
| 0.1% ointment | Active Comparator | Highest concentration |
|
| Placebo (vehicle without active) | Placebo Comparator | No active ingredient |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ZK245186 | Drug | Daily topical application |
|
| Measure | Description | Time Frame |
|---|---|---|
| Eczema Area and Severity Index (EASI) | Eczema area and severity index | At baseline |
| EASI | Ezcema area and severity index | Measured after one week of treatment |
| EASI | Eczema area and severity index | Measured at the end of 2 weeks of treatment |
| EASI | Eczema area and severity index | Measured at the end of 3 weeks of treatment |
| EASI | Eczema area and severity index | Measured at the end of 4 weeks of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Subjects' assessment of pruritus | Subjective measurement on a point scale | Measured at baseline |
| Subject's assessment of pruritus | Subjective measurement on a point scale |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Anaheim | California | 92801 | United States | |||
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo (vehicle without active ingredient) | Drug | Daily topical application |
|
| Measured after one week of treatment |
| Subject's assessment of pruritus | Subjective measurement on a point scale | Measured after two weeks of treatment |
| Subject's assessment of pruritus | Subjective measurement on a point scale | Measured after three weeks of treatment |
| Subject's assessment of pruritus | Subjective measurement on a point scale | Measured after four weeks of treatment |
| Honolulu |
| Hawaii |
| 96813 |
| United States |
| Boise | Idaho | 83704 | United States |
| Chicago | Illinois | 60612 | United States |
| Boston | Massachusetts | 02114-2508 | United States |
| Warren | Michigan | 48088 | United States |
| Fridley | Minnesota | 55432 | United States |
| New York | New York | 10029 | United States |
| Portland | Oregon | 97223 | United States |
| Austin | Texas | 78759 | United States |
| College Station | Texas | 77845 | United States |
| San Antonio | Texas | 78229 | United States |
| Webster | Texas | 77598 | United States |
| Kawaguchi Saitama | 332-0031 | Japan |
| Tokyo | 150-0034 | Japan |
| Tokyo | 162-0053 | Japan |
| ID | Term |
|---|---|
| D003876 | Dermatitis, Atopic |
| ID | Term |
|---|---|
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003872 | Dermatitis |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C546413 | R-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-(((2-methyl-5-quinolyl)amino)methyl)pentan-2-ol |
Not provided
Not provided
Not provided